PATRICK R. YASSINI
- Type
- Physician · Allopathic & Osteopathic Physicians / Family Medicine
- Where
- Coronado, CA
- NPI
- 1649353095
- Received
- $169,379 in 10 records, 2021 to 2025 ($281 general, $169,098 research)
- As principal investigator
- $2,567,645 of research payments to others in 653 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 1 | $23 |
| 2022 | General payment | 4 | $198 |
| 2022 | Research payment | 2 | $169,098 |
| 2021 | General payment | 3 | $60 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Valneva Austria GmbH | 2 | $169,098 | 2022 |
| Lumenis BE inc | 1 | $141 | 2022 |
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | 2 | $31 | 2022 |
| Linus Health, Inc. | 1 | $25 | 2022 |
| MERZ NORTH AMERICA, INC. | 1 | $23 | 2024 |
| Novo Nordisk Inc | 1 | $22 | 2021 |
| Clarus Therapeutics Inc. | 1 | $20 | 2021 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 2 | $169,098 |
| Food and Beverage | 8 | $281 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-10-07 | MERZ NORTH AMERICA, INC. | $23 | Food and Beverage | In-kind items and services | Xeomin Biological, Dermatology | 2024 | |
| 2022-08-17 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $17 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-05-17 | Lumenis BE inc | $141 | Food and Beverage (4 payments) | Cash or cash equivalent | OptiLight Device, Opthamology | 2022 | |
| 2022-03-28 | Valneva Austria GmbH | $87,208 | Research payment | Cash or cash equivalent | A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A L | 2022 | |
| 2022-03-14 | Valneva Austria GmbH | $81,889 | Research payment | Cash or cash equivalent | A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A L | 2022 | |
| 2022-03-11 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $13 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-02-08 | Linus Health, Inc. | $25 | Food and Beverage | In-kind items and services | CORE COGNITIVE EVALUATION Device, DEVICE | 2022 | |
| 2021-12-22 | Clarus Therapeutics Inc. | $20 | Food and Beverage | In-kind items and services | JATENZO Drug, Testosterone Replacement Therapy | 2021 | |
| 2021-12-07 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | RYBELSUS Drug, Diabetes | 2021 | |
| 2021-12-02 | Biohaven Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2021 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $2,780 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $911 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $905 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $637 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $330 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $330 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $330 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $330 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $330 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $330 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $330 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $330 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $330 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $330 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $905 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $905 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $905 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $905 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $905 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $905 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $905 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $905 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $905 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $905 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $905 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $905 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $905 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $905 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
| 2025-12-18 | Seqirus USA Inc | Apex Clinical Research | $905 | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Coronado, CA, county San Diego County, CA, state California; placed by its city name.
| Measure | Place (city or town) Coronado, CA | County San Diego County, CA | State California |
|---|---|---|---|
| Population B01003 | 19,015 | 3,288,774 | 39,287,377 |
| Population, 2020 census P1 | 20,192 | 3,298,634 | 39,538,223 |
| Median age B01002 | 42.0 | 37.3 | 37.9 |
| Under 18 B01001 | 17.8% | 20.9% | 22.0% |
| 65 and over B01001 | 22.1% | 15.4% | 15.7% |
| Households B11001 | 7,303 | 1,171,278 | 13,548,091 |
| Foreign born B05002 | 10.1% | 22.8% | 27.0% |
| Median household income B19013 | $134,534 | $106,268 | $99,122 |
| Median family income B19113 | $166,058 | $122,377 | $113,346 |
| Per capita income B19301 | $81,464 | $51,976 | $49,513 |
| Poverty rate B17001 | 4.7% | 10.3% | 12.0% |
| Unemployment rate B23025 | 4.7% | 6.1% | 6.6% |
| Civilian labor force B23025 | 6,805 | 1,689,384 | 20,068,466 |
| Mean commute (minutes) B08013 | 18.1 | 25.5 | 28.7 |
| Bachelor's degree or higher B15003 | 65.5% | 43.2% | 37.1% |
| Housing units B25001 | 9,896 | 1,250,641 | 14,644,735 |
| Owner-occupied B25003 | 54.6% | 54.6% | 55.9% |
| Renters B25003 | 45.4% | 45.4% | 44.1% |
| Median home value B25077 | $2,000,001 | $854,700 | $734,700 |
| Median gross rent B25064 | $3,257 | $2,246 | $2,036 |
| White, not Hispanic B03002 | 67.8% | 42.4% | 33.8% |
| Black B03002 | 2.4% | 4.4% | 5.2% |
| Hispanic or Latino B03002 | 20.2% | 34.6% | 40.2% |
| Asian B03002 | 3.3% | 12.1% | 15.3% |
| American Indian and Alaska Native B03002 | 0.4% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Coronado, CA.
Comments